Altimmune, Inc. (ALT)
3.675
-0.18
(-4.79%)
USD |
NASDAQ |
Dec 29, 16:00
3.65
-0.02
(-0.68%)
After-Hours: 20:00
Altimmune Shareholders Equity (Quarterly): 185.60M for Sept. 30, 2025
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Viking Therapeutics, Inc. | 713.03M |
| Amgen, Inc. | 9.619B |
| Rhythm Pharmaceuticals, Inc. | 148.82M |
| Terns Pharmaceuticals, Inc. | 284.07M |
| X4 Pharmaceuticals, Inc. | 61.62M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 218.45M |
| Total Liabilities (Quarterly) | 32.85M |
| Debt to Equity Ratio | 0.0857 |
| Current Ratio | 17.18 |
| Net Debt Paydown Yield | -0.78% |